What if your next trial could start faster, run smarter, and go further? In this issue, we spotlight regions streamlining approvals, frameworks raising the bar, and innovations that are no longer just on the horizon: An emerging market is quietly becoming the shortcut sponsors didn’t see coming. Mexico’s regula
regulatory
bioaccess® | Global Trial Accelerators™ | Fast-Tracking First-in-Human Trials, Anywhere
What if your next trial could start faster, run smarter, and go further? In this issue, we spotlight regions streamlining approvals, frameworks raising the bar, and innovations that are no longer just on the horizon:
Turn insights into action — your next trial opportunity starts here.
With its growing reputation as a clinical trial destination, Serbia is positioning itself as a regulatory sweet spot—offering European-aligned standards with fewer bureaucratic hurdles. Early-phase sponsors will find a system built for momentum: centralized ethics review, efficient timelines, and simplified import licensing processes make it a standout in Latin America.
Serbia delivers the compliance strength of the EU—without the friction. For sponsors eyeing Latin America, it’s a strategic choice for accelerating vaccine, Medtech, and Biopharma studies.
Mexico is reinforcing its position as a reliable destination for high-quality clinical research through a renewed collaboration between COFEPRIS and CONBIOÉTICA. The updated agreement strengthens the ethical and regulatory framework for clinical trials by integrating globally recognized standards—specifically the WHO Global Benchmarking Tool and ICH Good Clinical Practice (GCP) guidelines.
This integrated approach aims to improve study startup timelines, enhance participant protection, and ensure the scientific rigor needed to support international submissions—all while increasing coordination between regulatory and ethics committees.
Read the source at consultorsalud.com.mx
Does Your Company Need Accelerated First-in-Human Clinical Trial Results?
Overcome the complex landscape of first-in-human clinical trials with confidence. Whether you’re advancing Medtech devices, Biopharma therapies, or Radiopharmaceutical innovations, bioaccess® delivers expert solutions to help you succeed.
Schedule Your First-in-Human Trial Consult
When FastWave set out to test its neuromodulation device across two vastly different countries—Mexico and Uzbekistan—it encountered everything from mismatched tech infrastructure to culturally influenced patient hesitancy. Yet with careful planning, local CRO partnerships, and agile adaptation, both sites delivered on timelines and regulatory expectations.
This case study underscores the importance of region-specific strategy—even for a single protocol. For Medtech and Biopharma companies considering emerging markets, it’s a reminder that success lies in local insight, flexible operations, and early stakeholder alignment.
Read the source at clinicalleader.com
A recent early-phase study in Australia is marking progress in the development of a novel immunotherapy for autoimmune disease. Following positive safety results from the first multiple-dose cohort, the program is now moving forward—highlighting Australia’s growing role in advancing first-in-human and exploratory trials in complex indications.
Read the source at biotechdispatch.com.au
A new monoclonal antibody for severe asthma, designed using artificial intelligence, is heading into two global Phase 3 trials spanning over 40 countries—including Mexico. The therapy targets TSLP, a key inflammatory cytokine, and is optimized for just two doses per year, potentially transforming treatment models for chronic respiratory disease.
Mexico’s participation in late-stage studies for advanced biologics signals rising confidence in the region’s clinical trial capabilities—especially for programs backed by cutting-edge technologies like AI.
Read the source at mexicobusiness.news
With FDA clearance secured for urologic procedures, the Hugo robotic-assisted surgery system is officially entering the U.S. market—marking a major milestone in the evolution of surgical robotics. Already active in over 30 countries, the system brings a modular architecture, an open console design, and integrated digital capabilities aimed at enhancing surgical precision and workflow efficiency.
This move signals a broader shift in the Medtech landscape as robotic systems become increasingly connected, ergonomic, and data-driven. As platforms like Hugo scale globally, the downstream impact on device trials, usability studies, and surgical integration is set to grow—creating new opportunities for early-phase research and market entry planning.
Read the source at medtechdive.com
← All Global Trial Accelerators editions · Contact bioaccess®